<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02954497</url>
  </required_header>
  <id_info>
    <org_study_id>C01367</org_study_id>
    <nct_id>NCT02954497</nct_id>
  </id_info>
  <brief_title>Pumps for Kids, Infants, and Neonates</brief_title>
  <acronym>PumpKIN</acronym>
  <official_title>Pumps for Kids, Infants, and Neonates</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HealthCore-NERI</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jarvik Heart, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>HealthCore-NERI</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PumpKIN is a multicenter, prospective, single-arm feasibility study; Evaluating the
      investigational Jarvik 2015 VAD in pediatric patients with heart failure. This feasibility
      trial will enroll 10 subjects at up to 7 sites in the US.

      The primary objectives of this investigational device exemption (IDE) clinical investigation
      are to assess the feasibility of using the Jarvik 2015 in pediatric patients with severe
      heart failure who require mechanical circulatory support. Feasibility will be assessed by
      evaluating the safety profile of the Jarvik 2015 device in eligible subjects.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 22, 2018</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>• To assess the clinical feasibility of the investigational Jarvik 2015 VAD by evaluating survival in the absence of severe neurological impairment or death, or device failure up to the clinical endpoint</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Pediatric Heart Failure</condition>
  <arm_group>
    <arm_group_label>Jarvik 2015 Device VAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>New, experimental continuous flow VAD</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Surgical placement of the Jarvik 2015 VAD</intervention_name>
    <description>The Jarvik 2015 VAD is a miniaturized, fully implantable, continuous flow left ventricular assist device.</description>
    <arm_group_label>Jarvik 2015 Device VAD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgical Placement of Jarvik 2015 VAD</intervention_name>
    <description>Surgical Implant of the Jarvik 2015 VAD is a miniaturized, fully implantable, continuous flow left ventricular assist device.</description>
    <arm_group_label>Jarvik 2015 Device VAD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        All children with severe (Ross or New York Heart Association (NYHA) class IV) heart failure
        despite optimal medical therapy (INTERMACS profiles for pediatrics: Profiles 1 or 2) who
        require mechanical circulatory support and meet the following criteria:

          1. Males and females within weight range: 8.0 Kg ≤ weight ≤ 30.0 Kg

          2. Males and females within Body surface area (BSA) range: 0.4 m2 ≤ BSA ≤ 1.0 m2

          3. Cardiac anatomy categories:

               1. Standard Cardiac Anatomy: Two-ventricle circulation, including cardiomyopathy,
                  repaired structural heart disease (e.g. anomalous left coronary artery from the
                  pulmonary artery [ALCAPA], aortic stenosis) or acquired heart disease (e.g.,
                  myocarditis, Kawasaki disease)

               2. Challenging Cardiac Anatomy: Any challenging cardiac anatomy (including but not
                  limited to single ventricle heart disease) that, in the opinion of the
                  investigator with confirmation from one of the DCCC Clinical PIs, is difficult to
                  support with available (e.g. pulsatile) devices.

          4. INTERMACS Profile 1 or 2 as evidenced by:

               1. Inability to wean from extra-corporeal membrane oxygenation (ECMO) or other
                  temporary circulatory support (TCS), OR

               2. Inability to wean from mechanical ventilator support, OR

               3. Inotrope-dependent, decompensated heart failure AND meet one or more of the
                  following criteria within 48 hours prior to implant (unless otherwise noted)
                  which is attributed to decompensated heart failure despite optimal medical
                  therapy:

             i. Urine output &lt;0.5 cc/kg/hour for 12hr within 48 hours prior to implant ii.
             Creatinine level &gt;2 times the upper limit of normal (ULN) for age iii. Alanine
             aminotransferase (ALT) or total bilirubin level &gt;3 times the ULN for age (either
             qualifies the patient) iv. Mixed venous oxygen saturation (SvO2) &lt;55% (or
             arteriovenous oxygen difference &gt;45%) in two repeated measurements v. Acidosis: Base
             excess &gt;-5 in 2 or more measurements vi. Inability to tolerate appropriate enteral
             calories as prescribed by a registered dietician vii. Inability to ambulate freely to
             participate fully in age-appropriate activities of daily living (ADLs) and/or cardiac
             rehabilitation/physical therapy, OR

          5. LVAD support is intended for bridge-to transplant. Subject is listed for transplant or
             eligible (i.e., no medical or surgical contraindications) to be listed for cardiac
             transplant, United Network for Organ Sharing (UNOS) status 1A, or equivalent

          6. Written consent of parent(s) or legally authorized representative (LAR) where
             appropriate.

        Exclusion Criteria

        To be eligible for this trial, the subjects must meet none of the following exclusion
        criteria within 48 hours prior to device implant:

          1. Known contraindication to systemic anticoagulation

          2. Currently participating in an interventional trial whose protocol prevents effective
             application of the Jarvik 2015 device, potentially has an independent effect on trial
             endpoints, or otherwise interferes with execution of the PumpKIN protocol

          3. Stable inotrope dependence (INTERMACS profile 3)

          4. Single ventricle anatomy

          5. Presence of a mechanical heart valve

          6. Unresolved malignancy

          7. CPR with duration &gt; 30 consecutive minutes within 48 hours prior to device implant or
             CPR with uncertain neurological status

          8. Renal dysfunction that is severe or, in the opinion of the investigator, irreversible

          9. Hepatic dysfunction that is severe or, in the opinion of the investigator,
             irreversible

         10. Severe or irreversible pulmonary dysfunction

         11. ECMO use for &gt; 10 consecutive days

         12. Unrepairable severe aortic insufficiency

         13. Active, systemic infection unresponsive to antimicrobials therapy

         14. Known cerebrovascular event within the past 30 days or uncertain neurological status

         15. Severe right ventricular (RV) dysfunction or significant arrhythmia requiring
             treatment with an RV assist device (RVAD) (i.e., biventricular assist device)

         16. Unmanageable bleeding per judgment of the investigator

         17. Ventricular dysfunction that is likely to recover (e.g. myocarditis, metabolic
             myopathy where LV dysfunction is present solely with intermittent acidosis/crises).

         18. Left ventricular end-diastolic dimension or left ventricular end-diastolic volume z
             score of &lt; +2.5

         19. Left ventricular ejection fraction of &gt;35%
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William T Mahle, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Children's Hospital of Atlanta, Emory University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sandra Siami, MPH</last_name>
    <phone>6179723317</phone>
    <email>ssiami@neriscience.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lucile Packard Children's Hospital Stanford</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Rosenthal, MD</last_name>
      <email>davidnr@stanford.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kirk Kanter, MD</last_name>
      <phone>404-785-6330</phone>
      <email>kkanter@emory.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francis Flynn-Thompson, MD</last_name>
      <email>Francis.Fynn-Thompson@cardio.chboston.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Chai, MD</last_name>
      <phone>212-305-5975</phone>
      <email>pjc@cumc.columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Morales, MD</last_name>
      <email>david.morales@cchmc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Medical Center - Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryan Davies, MD</last_name>
      <phone>214-456-5000</phone>
      <email>ryan.davies@utshouthwestern.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iki Adachi, MD</last_name>
      <email>ixadachi@texaschildrens.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>October 31, 2016</study_first_submitted>
  <study_first_submitted_qc>November 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2016</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Limited use data set will be made available through NHLBI after the conclusion of the trial.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

